INDOCO vs ZIMLAB: Stock Comparison

Indoco Remedies Limited vs Zim Laboratories Limited

Live data: 22 July 2026, 2:52 PM IST • Source: NSE and company filings

Indoco Remedies Limited is the larger company by market capitalisation. Indoco Remedies Limited shows a lower P/E, a higher dividend yield and faster revenue growth, while Zim Laboratories Limited shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Indoco Remedies Limited and Zim Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, INDOCO is more favourable on 7 of 13 scored metrics and ZIMLAB on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
INDOCO is the larger company
₹2,160 Cr vs ₹656 Cr
P/E Ratio
INDOCO has a lower P/E
-23.83x vs 112.39x
P/B Ratio
ZIMLAB has a lower P/B
2.21x vs 2.41x
EPS
ZIMLAB has higher earnings per share
₹1.94 vs ₹-10.71
Dividend Yield
INDOCO has a higher dividend yield
0.08% vs 0.02%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs -3.36%
EPS Growth (TTM YoY)
INDOCO has faster EPS growth
0% vs -47.01%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
21.9% vs -12.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOCOZIMLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDOCOZIMLAB
Live Price₹233.99₹104.91
Day Change-4.82%0.25%
Volume71,68881,241
52-Week High₹336₹121.47
52-Week Low₹162.19₹59.31
Distance from 52W High-30.36%-13.63%

Valuation

MetricINDOCOZIMLAB
Market Cap₹2,160 Cr₹656 Cr
P/E Ratio-23.83x112.39x
P/B Ratio2.41x2.21x
EPS₹-10.71₹1.94
Book Value₹111.55₹51.77
Dividend Yield0.08%0.02%

Growth

MetricINDOCOZIMLAB
Revenue Growth (TTM YoY)21.9%-3.36%
EPS Growth (TTM YoY)0%-47.01%
Qtr Sales Growth21.9%-12.3%
Qtr Profit Growth39%-308%

Profitability & Leverage

MetricINDOCOZIMLAB
ROE-9.42%1.97%
ROCE0.93%8.16%
Net Margin-5.31%1.56%
Operating Margin7.68%5.72%
Debt to Equity1.16x0.42x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOCOZIMLAB
Promoter Holding58.86%30.36% 0.01 pp
FII Holding1.27% 0.33 pp0.03% 0.03 pp
DII Holding17.68% 0.47 pp1.33% 1.26 pp
Public Holding22.04% 0.14 pp68.28% 1.3 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Indoco Remedies Limited and Zim Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.